Biomarin Pharmaceutical earnings were -$19.1M for the trailing 12 months ending Sep 30, 2026, with N/A growth year over year. The latest BMRN earnings report on Sep 30, 2026 announced Q3 2026 earnings of -$122.8M, down 374.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, BMRN reported annual earnings of $348.9M, with -18.3% growth.
Biomarin Pharmaceutical Earnings Reports & History FAQ
What were Biomarin Pharmaceutical's earnings last quarter?
On BMRN's earnings call on Nov 2, 2026, Biomarin Pharmaceutical (NASDAQ: BMRN) reported Q3 2026 earnings per share (EPS) of -$0.63, up 293.75% year over year. Total BMRN earnings for the quarter were -$122.83 million. In the same quarter last year, Biomarin Pharmaceutical's earnings per share (EPS) was -$0.16.
Is Biomarin Pharmaceutical profitable or losing money?
As of the last Biomarin Pharmaceutical earnings report, Biomarin Pharmaceutical is currently losing money. Biomarin Pharmaceutical's net profit (also called net income) for the twelve months ending Sep 30, 2026 was -$19.12 million, a 103.67% decrease year over year.
What was BMRN's earnings growth in the past year?
As of Biomarin Pharmaceutical's earnings date in Nov 2, 2026, Biomarin Pharmaceutical's earnings has grown year over year. BMRN earnings in the past year totalled -$19.12 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.